Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se ADR
(NQ:
ARGX
)
359.42
-2.16 (-0.60%)
Streaming Delayed Price
Updated: 10:38 AM EDT, May 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Argenx Se ADR
< Previous
1
2
3
Next >
argenx to Report Half Year 2023 Financial Results and Second Quarter Business Update on July 27, 2023
July 20, 2023
From
argenx SE
Via
GlobeNewswire
argenx announces full exercise of underwriters’ option to purchase additional ADSs
July 19, 2023
From
argenx SE
Via
GlobeNewswire
argenx raises $1.1 billion in gross proceeds in a global offering
July 18, 2023
From
argenx SE
Via
GlobeNewswire
argenx announces launch of proposed global offering
July 17, 2023
From
argenx SE
Via
GlobeNewswire
argenx SE (NASDAQ: ARGX) Leading the Way in Monday Trading Based on Percentage Gain
July 17, 2023
Via
Investor Brand Network
Zai Lab and argenx Report Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023
From
Zai Lab Limited
Via
GlobeNewswire
argenx Reports Positive Topline Data from ADHERE Study of VYVGART Hytrulo in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
July 17, 2023
From
argenx SE
Via
GlobeNewswire
argenx and Zai Lab Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
June 30, 2023
From
argenx SE
Via
GlobeNewswire
Zai Lab and argenx Announce Approval of VYVGART® (efgartigimod alfa injection) for Generalized Myasthenia Gravis in China
June 30, 2023
From
Zai Lab Limited
Via
GlobeNewswire
argenx Announces U.S. Food and Drug Administration Approval of VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Generalized Myasthenia Gravis
June 20, 2023
From
argenx SE
Via
GlobeNewswire
argenx Initiates Second Cohort of Phase 2 ARDA Study of Empasiprubart in Multifocal Motor Neuropathy
June 20, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
May 31, 2023
From
argenx SE
Via
GlobeNewswire
argenx Reports First Quarter 2023 Financial Results and Provides Business Update
May 04, 2023
From
argenx SE
Via
GlobeNewswire
argenx announces results of Annual General Meeting of Shareholders
May 03, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at BofA Securities 2023 Health Care Conference
May 02, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Report First Quarter 2023 Financial Results and Business Update on May 4, 2023
April 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx Demonstrates Commitment to Redefining Treatment Goals for Generalized Myasthenia Gravis with Multiple Presentations at American Academy of Neurology 2023 Annual Meeting
April 18, 2023
From
argenx SE
Via
GlobeNewswire
argenx and Genmab Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
April 17, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces Annual General Meeting of Shareholders on May 2, 2023
March 17, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces UK MHRA Approval of VYVGART for the Treatment of Generalized Myasthenia Gravis
March 15, 2023
From
argenx SE
Via
GlobeNewswire
argenx Reports Full Year 2022 Financial Results and Provides Fourth Quarter Business Update
March 02, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces Planned Transition of Chief Operating Officer
March 02, 2023
From
argenx SE
Via
GlobeNewswire
argenx Appoints Steve Krognes to Board of Directors
February 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at Upcoming Investor Conferences
February 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Report Full Year 2022 Financial Results and Fourth Quarter Business Update on March 2, 2023
February 23, 2023
From
argenx SE
Via
GlobeNewswire
argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod
January 27, 2023
From
argenx SE
Via
GlobeNewswire
argenx Announces Extraordinary General Meeting of Shareholders on February 27, 2023 to Appoint Steve Krognes as Non-Executive Director
January 16, 2023
From
argenx SE
Via
GlobeNewswire
argenx Highlights 2023 Strategic Priorities Across Immunology Pipeline
January 09, 2023
From
argenx SE
Via
GlobeNewswire
argenx to Present at 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
argenx SE
Via
GlobeNewswire
argenx Appoints Ana Cespedes to Board of Directors
December 12, 2022
From
argenx SE
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.